Probiotic Supplementation Shows Promise in Alleviating COPD Symptoms

What's new

Emerging research is investigating the role of gut-focused interventions, such as probiotics, in managing symptoms associated with chronic obstructive pulmonary disease (COPD). A new exploratory randomized controlled trial examined the effects of an 8-week course of a multistrain probiotic supplement on individuals with mild-to-moderate COPD. The study observed that participants receiving the probiotic reported an improvement in their overall daily symptoms compared to those on a placebo. However, the intervention did not lead to measurable changes in objective clinical outcomes like lung function or the severity of shortness of breath [1].

The science behind it

This randomized controlled trial involved 44 participants, with an average age of 63, all diagnosed with mild-to-moderate COPD. For eight weeks, participants were randomly assigned to either receive a daily multistrain probiotic supplement or a placebo. The probiotic formulation contained a total of 34 billion colony-forming units (CFU) from various strains, including Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium longum, and Streptococcus thermophilus [1].

The primary findings indicated that the probiotic group experienced a reduction in their overall symptom scores when compared to the placebo group. This suggests a subjective improvement in how participants felt day-to-day. However, objective measures of lung function, which typically include parameters like forced expiratory volume in one second (FEV1), did not show significant improvement. Similarly, there was no notable change in reported shortness of breath, a common and debilitating symptom of COPD [1].

Beyond clinical symptoms, the study also investigated inflammatory markers. Probiotic supplementation was associated with a reduction in interleukin-6 (IL-6), a pro-inflammatory cytokine often elevated in chronic inflammatory conditions like COPD. However, two other inflammatory markers assessed in the study did not show a significant response to the probiotic intervention. The precise mechanisms by which probiotics might influence COPD symptoms are still being explored, but they are thought to involve modulation of the gut microbiome, which can, in turn, affect systemic inflammation and immune responses [1].

What it means in practice

For individuals living with mild-to-moderate COPD, these findings suggest that multistrain probiotic supplementation might offer some symptomatic relief, particularly in terms of overall daily well-being. The improvement in self-reported symptoms, even without changes in objective lung function, could be meaningful for quality of life. This positions probiotics as a potential complementary therapy rather than a primary treatment for the underlying disease progression [1].

It is important to note that while the reduction in IL-6 is an interesting biological finding, its clinical significance in this context requires further investigation. Patients considering probiotic supplementation for COPD should discuss it with their healthcare provider, as it should not replace established medical treatments. The study's exploratory nature and relatively small sample size mean that these results are promising but preliminary [1].

Caveats

This study was an exploratory randomized controlled trial with a modest sample size of 44 participants, which limits the generalizability and definitive conclusions that can be drawn. The duration of the intervention was 8 weeks, which may not be long enough to observe more substantial or lasting changes in complex conditions like COPD. While subjective symptom improvement was noted, the lack of impact on objective measures such as lung function and shortness of breath indicates that probiotics may not alter the fundamental physiological aspects of the disease [1].

Furthermore, the specific multistrain probiotic blend used in this study may not yield identical results with other probiotic formulations, as effects can be strain-specific. The study focused on mild-to-moderate COPD, so the findings may not apply to individuals with more severe forms of the disease. Larger, longer-term trials are needed to confirm these preliminary findings, elucidate the mechanisms of action, and determine the optimal probiotic strains and dosages for COPD management [1].

Source: [1] https://examine.com/research-feed/study/1lM6E0/